In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for ...

The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...

A panelist discusses how type 1 diabetes (T1D) is a complex autoimmune disease characterized by progressive beta cell destruction that advances through distinct stages, with genetic predisposition, ...

The HHS secretary’s plans would create a new Administration for a Healthy America (AHA) subagency and slash the department’s workforce by 25%, including 3,500 full-time positions at the FDA.

During last year’s enrollment period, millions of Medicare beneficiaries reviewed their coverage options and selected new Medicare plans for the 2025 calendar year due to changes including the plans ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Division of HIV Prevention tracks outbreaks, provides education and establishes guidelines for the United States and the ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.